The technology we use is built on 15 years of research at Philips, and exclusively licensed to HEMEO. The computational model at the core of Hemeo 2.0 captures the whole coagulation complexity, consolidates it and makes it available in an easy-to-use interface.
HEMEO’s core technology is a computational model of the blood coagulation system that has been validated with laboratory data from thousands of people.
Supplied with a single patient’s laboratory data, the model can make personalized thrombosis and bleeding risk predictions and personalized treatment recommendations.
The insight provided by Hemeo’s intuitive clinical decision support software provides physicians with such patient specific guidance that it has the power to significantly reduce the number of bleeding and thrombosis instances in ICU patients.
We would like you to have a first hand experience with our model demo. If you send us your contact details and a
short explanation of how you would use the model, we’ll share an access link.
A validation of our patent that describes the use of our knowledge-based coagulation model for the analysis of the thrombin generation assay to accurately derive the fibrinogen concentration.
Our model provides a clinically applicable method to identify sepsis/SIRS patients with a high probability to develop DIC well in advance.